{"schema_version":"secwatch.filing_event.v1","accession":"0001006837-23-000127","form_type":"8-K","ticker":"VATE","cik":"0001006837","company_name":"INNOVATE Corp.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.824536+00:00","generated_at":"2026-06-08T05:59:48.502520+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"INNOVATE Q3 rev $375M (-11% YoY), Adj EBITDA $22.1M (+35%); extends note maturity to 2025","bullets":["Net loss $7.3M ($0.09/sh) flat YoY; Adj EBITDA $22.1M vs $16.4M (+34.8%).","Infrastructure DBM Global rev $369.3M (-10.5%), Adj EBITDA margin 8.3% (+170bps), backlog $1.3B.","Spectrum rev $5.4M (-41%) due to Azteca closure; exploring datacasting partnerships with HPE and PBS.","Life Sciences rev $0.6M, loss narrows; MediBeacon continues FDA approval process.","Post-quarter: extended $69.7M secured notes maturity to Aug 2025; INNOVATE to use sale proceeds for repayment."],"urls":{"canonical":"https://secwatch.observer/filing/0001006837-23-000127","json":"https://secwatch.observer/filing/0001006837-23-000127.json","markdown":"https://secwatch.observer/filing/0001006837-23-000127.md","text":"https://secwatch.observer/filing/0001006837-23-000127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006837/000100683723000127/0001006837-23-000127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006837/000100683723000127/hchc-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:59:48.502520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6422bef6597be174a76de9472e753b0648037702","claim":"INNOVATE Corp. reported third quarter 2023 results: revenue $375.3 million, net income Net loss attributable to common stockholders of $7.3 million, EPS $0.09 per fully diluted share.","evidence_excerpt":"Adjusted EBITDA (1) $ 22.1 $ 16.4 34.8 % $ 43.5 $ 40.0 8.7 % (1) Reconciliation of GAAP to Non-GAAP measures follows Commentary “INNOVATE delivered third quarter revenue of $375.3 million and experienced strong Adjusted EBITDA growth of 34.8%, which was primarily driven by our Infrastructure and Life Sciences operating segments,\" said Avie Glazer, Chairman of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006837/000100683723000127/0001006837-23-000127-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Revenue","value":"$375.3 million"},{"label":"Net income","value":"Net loss attributable to common stockholders of $7.3 million"},{"label":"EPS","value":"$0.09 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}